5-Amino-1MQ

5-Amino-1-methylquinolinium (5-amino-1MQ) is a non-peptide small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that catalyzes the methylation of nicotinamide using S-adenosyl methionine (SAM) as a methyl donor; NNMT is overexpressed in adipose tissue and has been identified as a metabolic regulator linking one-carbon metabolism, cellular methylation capacity, and adipogenesis. NNMT inhibition by 5-amino-1MQ is proposed to increase intracellular SAM and polyamine availability, shifting the cellular methylation balance in adipocytes toward suppression of adipogenesis and promotion of thermogenic gene expression; preclinical studies have examined effects on adipose tissue energy expenditure, systemic metabolism, and gut microbiome composition in diet-induced obesity mouse models.

fat cell reduction, metabolic rate, adipose tissue modulation.

Research on 5-Amino-1MQ primarily documents effects related to fat cell reduction and metabolic rate and adipose tissue modulation. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

For 5-Amino-1MQ, it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

39 providers in the directory currently offer 5-Amino-1MQ.

Across 20 research vendors tracked on PeptideBase, 5-Amino-1MQ has a median price of about $5.00 per mg, typically ranging $2.88–$8.00 per mg. This reflects research-use vendor pricing, not clinical or prescription costs.

Research in diet-induced obese mice found that NNMT inhibition with a small-molecule inhibitor (related to 5-amino-1MQ) significantly reduced body weight and fat mass and increased energy expenditure, identifying NNMT as a potential metabolic target for obesity.